Clinical trials: Buruli Ulcer
Buruli Ulcer
Thermotherapy of Buruli Ulcer at Community Level in the Health District of Akonolinga
The project rolls out combined innovative low-tech thermotherapy of Buruli ulcer (BU) with heat packs and WHO recommended wound management in a BU endemic district of Cameroon.
- Trial name
- UB Thermo (NCT03969940)
- Sponsor
- Swiss Tropical & Public Health Institute
Skin Ulcer, Buruli Ulcer
Treat Early and Broad: Thermotherapy of Buruli Ulcer Integrated Into WHO-recommended Wound Management in West Africa
The project rolls out combined innovative low-tech thermotherapy with heat packs and WHO recommended wound management in a Buruli ulcer (BU)-endemic district of West Africa.
- Conditions
- Skin Ulcer, Buruli Ulcer, Nontuberculous Mycobacteria
- Trial name
- WOUNDCARE (NCT03957447)
- Testing
- thermotherapy (application of heat): This part of the trial is on hold due to the Covid19-pandemia
- Where
- Côte d’Ivoire
- Volunteers
- 5,000 people
- Sponsor
- University Hospital Heidelberg
Mycobacterium Ulcerans Infection
WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8
This is a WHO-sponsored trial. Combination therapy with streptomycin and rifampicin has been the standard antibiotic treatment for M. ulcerans infection since 2004.
- Trial name
- NCT01659437
- Testing
- Clarithromycin Extended Release, Streptomycin intramuscular injection
- Where
- 5 sites in Benin, Ghana
- Volunteers
- 310 people
- Sponsor
- University Medical Center Groningen
Buruli Ulcer
Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy
Buruli ulcer (BU) is a skin Neglected Tropical Disease (NTD) that is caused by Mycobacterium ulcerans. It affects skin, soft tissues and bones causing long-term morbidity, stigma and disability.
- Trial name
- BLMs4BU (NCT05169554)
- Testing
- Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks., Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks.
- Where
- 3 sites in Benin
- Volunteers
- 140 people
- Sponsor
- Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)
Mycobacterium Ulcerans Disease, Buruli Ulcer
Timing of Surgical Intervention in Buruli Ulcer Patients Treated With Antibiotics
SUMMARY Rationale: Buruli ulcer, caused by Mycobacterium ulcerans, is an ulcerative disease endemic in West Africa. It often leads to functional limitations.
- Trial name
- Burulitime (NCT01432925)
- Testing
- surgical intervention on Buruli ulcer
- Where
- 2 sites in Benin
- Volunteers
- 119 people
- Sponsor
- University Medical Center Groningen
Mansonella Perstans Infection, Buruli Ulcer
Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana
This study will determine the influence of doxycycline treatment against Wolbachia/M. perstans on immunity against concomitant mycobacterial infections in healthy M. perstans infected individuals.
- Conditions
- Mansonella Perstans Infection, Buruli Ulcer, Tuberculosis, Co-infection
- Trial name
- Map2Co (NCT02281643)
- Testing
- Doxycycline
- Where
- Ghana
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Kwame Nkrumah University of Science and Technology
Leprosy, Buruli Ulcer
Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
Appropriate targeting of interventions for neglected tropical diseases (NTDs) that require innovative and intensified disease management (IDM) requires accurate data on the distribution of these diseases within endemic countries.
- Conditions
- Leprosy, Buruli Ulcer, Yaws, Lymphatic Filariases
- Trial name
- NCT03683745
- Where
- Liberia
- Volunteers
- 56,285 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Buruli Ulcer, Mycobacterium Ulcerans Disease
Pathogenesis and Management of M. Ulcerans Disease, Buruli Ulcer
Buruli ulcer is a neglected tropical disease caused by infection with Mycobacterium ulcerans (Mu) in rural parts of West Africa. It causes large skin ulcers mainly in children aged 5 to 15 years.
- Trial name
- Buruli_Path (NCT02153034)
- Where
- 3 sites in Ghana
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Kwame Nkrumah University of Science and Technology
Buruli Ulcer, Mycobacterium Ulcerans
BURULICO Drug Trial Study Protocol: RCT SR8/SR4+CR4, GHANA
The standard for treatment Buruli ulcer disease (BUD) used to be surgery but the WHO now advises streptomycin (S, 15 mg/kg daily, intramuscularly) and rifampicin (R,10 mg/kg daily) along with surgery.
- Trial name
- BURULICO (NCT00321178)
- Testing
- SR4 - switch to CR4
- Where
- 2 sites in Ghana
- Volunteers
- 151 people
- Sponsor
- University Medical Center Groningen
Skin and Connective Tissue Diseases, Neglected Tropical Diseases
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited.
- Conditions
- Skin and Connective Tissue Diseases, Neglected Tropical Diseases, Leprosy, Buruli Ulcer
- Trial name
- SkincAIr (NCT07506967)
- Testing
- A mobile app with AI functionality for diagnosing skin-related NTDs
- Where
- 5 sites in Democratic Republic of the Congo, Ethiopia and 3 more
- Volunteers
- 2,420 people
- Sponsor
- Kenya Medical Research Institute